Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Abpro CorpABP · Entity 166815 | Director | May 10, 2018 | May 11, 2018 |
| Cellectar Biosciences, Inc.CLRB · Entity 7572 | Director | July 07, 2026 | July 09, 2026 |
| Conformis IncCFMS · Entity 109987 | INTERIM CFO & INTERIM TREAS | October 23, 2019 | October 28, 2019 |
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | January 02, 2025 | January 03, 2025 |
| ImmunityBio, Inc.NK · Entity 3618 | Director | August 11, 2020 | August 13, 2020 |
| Invivyd, Inc.IVVD · Entity 721 | Interim CFO | October 13, 2022 | October 13, 2022 |
| Lite Strategy, Inc.LITS · Entity 7396 | Director | November 14, 2025 | November 18, 2025 |
| Renovacor, Inc.RCOR · Entity 114644 | Chief Financial Officer | March 28, 2022 | March 28, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Abpro Corp
Report date May 10, 2018 · Filed May 11, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,089 |
Reported balance
Holding disclosure · report date 2018-05-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 25,089 F1: This security represents restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. 25% of the RSU shall vest on August 31, 2018; the remainder will vest in equal monthly installments over the 36 month period following August 31, 2018, subject to continuous service by the Reporting Person to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This security represents restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. 25% of the RSU shall vest on August 31, 2018; the remainder will vest in equal monthly installments over the 36 month period following August 31, 2018, subject to continuous service by the Reporting Person to the Issuer on each such date.
Cellectar Biosciences, Inc.
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2036-07-07 | Direct | 25,000 |
Reported balance
After 2026-07-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-07 · Grant · Acquired 25,000 · Balance 25,000 F1: This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.
Conformis Inc
Report date October 23, 2019 · Filed October 28, 2019
This filing explicitly reported no securities owned.
Cue Biopharma, Inc.
Report date January 02, 2025 · Filed January 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2035-01-01 | Direct | 24,400 |
Reported balance
After 2025-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 24,400 · Balance 24,400 F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2: This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.
F2: This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date.
ImmunityBio, Inc.
Report date August 11, 2020 · Filed August 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,235 |
Ending reported balance
After 2020-08-11 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-08-11 · Sale · Disposed 50,000 · Balance 124,535 F1: Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person. F2: Represents the weighted average share price of an aggregate total of 50,000 shares sold in the price range of $9.89 to $10.7275 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2020-08-11 · Sale · Disposed 10,000 · Balance 114,535 F1: Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person. F3: Represents the weighted average share price of an aggregate total of 10,000 shares sold in the price range of $9.94 to $10.0301 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2020-08-11 · Sale · Disposed 5,300 · Balance 109,235 F1: Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person. F4: Represents the weighted average share price of an aggregate total of 5,300 shares sold in the price range of $10.50 to $11.07 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person.
F2: Represents the weighted average share price of an aggregate total of 50,000 shares sold in the price range of $9.89 to $10.7275 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average share price of an aggregate total of 10,000 shares sold in the price range of $9.94 to $10.0301 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: Represents the weighted average share price of an aggregate total of 5,300 shares sold in the price range of $10.50 to $11.07 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Invivyd, Inc.
Report date October 13, 2022 · Filed October 13, 2022
This filing explicitly reported no securities owned.
Lite Strategy, Inc.
Report date November 14, 2025 · Filed November 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2035-11-14 | Direct | 55,000 |
Reported balance
After 2025-11-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-14 · Grant · Acquired 55,000 · Balance 55,000 F2: Received as compensation for service on the Board. F1: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026.
F2: Received as compensation for service on the Board.
Renovacor, Inc.
Report date March 28, 2022 · Filed March 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2032-03-28 | Direct | 155,325 |
Reported balance
After 2022-03-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-28 · Grant · Acquired 155,325 · Balance 155,325 F1: The stock option will vest and become exercisable in full on March 28, 2026, with 25% vesting on March 28, 2023, and the remainder vesting in equal monthly installments for the remaining 36 months, subject to the continuous service of the Reporting Person on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest and become exercisable in full on March 28, 2026, with 25% vesting on March 28, 2023, and the remainder vesting in equal monthly installments for the remaining 36 months, subject to the continuous service of the Reporting Person on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 30,680 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2031-05-31 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 168,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F3: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2016 Filed Dec 27, 2016 22:00 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | OtherCommon Stock | 1,134 | $9.01 | $10,217.34 |
DisclosureSEC source: 0001209191-16-156828 · doc4.xml · nonDerivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,531 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,134 shares by the Reporting Person on December 20, 2016 pursuant to the Issuer's Employee Stock Purchase Plan. F1 · shares: This Form 4 is being filed voluntarily to report the acquisition of 1,134 shares by the Reporting Person on December 20, 2016 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.